2717 Partners

2717 Partners

2717 Partners launched in 2018 as a healthcare-focused investment vehicle, continuing the partnership model its principals have refined since the 1990s. Chairman Lindsay Rosenwald, a physician-turned-investment-banker, built his reputation at Oppenheimer and Paramount BioCapital, where he created a pipeline of publicly traded biotech companies. Managing Members Fred Dwek and Michael Weiss bring parallel operating and legal expertise from prior ventures, including Fortress Biotech and various Rosenwald-affiliated entities. The firm does not manage third-party capital in a blind-pool format; it uses its own balance sheet to seed new entities. The strategy centers on founding and capitalizing clinical-stage biotechnology companies targeting oncology, rare diseases, and genetic disorders. The group typically builds a biotech around a licensed molecule from an academic institution, hires a management team, and takes the company public on NASDAQ within two years. Unlike a traditional venture fund, 2717 Partners generates realized returns through structured exits, royalties, and public-market sales rather than waiting for binary acquisition outcomes. Portfolio companies historically connected to the team include Checkpoint Therapeutics, Mustang Bio, and Avenue Therapeutics (per SEC filings, 2015–2020). The firm's model creates a steady cadence of IPOs — Rosenwald has been associated with more than 20 biotech IPOs over his career. Rosenwald and his co-managers have founded or financed dozens of biotech names through predecessor vehicles, including Opus Point Partners and Fortress Biotech. The team structure blurs the line between a family office, a hedge fund, and a venture studio — they take board seats, contribute scientific advisory support, and manage syndicate relationships across the capital stack. Their reach extends to partnerships with major cancer centers and licensing from institutions such as the National Institutes of Health and Memorial Sloan Kettering. No dedicated philanthropic arm is publicly disclosed, though the principal's medical background informs the clinical-mission focus. The group's structural differentiator is its status as a repeat biotech founder, not just a financial investor — 2717 Partners manufactures public companies as its primary product. Where typical biotech VCs rely on a small number of massive exits to drive returns, the Rosenwald-Dwek-Weiss model harvests frequent, smaller-scale public listings and royalty streams. That approach reduces binary exit risk and creates a perpetual pipeline of investable assets, though it also exposes the portfolio to public-market biotech sentiment cycles and the increasing costs of maintaining multiple listed entities.